No­var­tis' San­doz set­tles with No­vo Nordisk for 2024 launch of third Vic­toza gener­ic

Al­though the patents on the ac­tive in­gre­di­ent of No­vo Nordisk’s GLP-1 block­buster Vic­toza for Type 2 di­a­betes ex­pire next year, the com­pa­ny agreed in a set­tle­ment yes­ter­day that a gener­ic ver­sion of the GLP-1 from No­var­tis sub­sidiary San­doz can launch in June 2024.

“San­doz is li­censed to launch a gener­ic ver­sion of Vic­toza as of 22 June 2024, or ear­li­er un­der cer­tain cir­cum­stances,” a spokesper­son for No­vo told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.